In 1954, the company expanded operations outside of the United States by opening an office in Belgium. In 1956 Baxter International introduced the first functioning artificial kidney, and in 1971 became a member of the Fortune 500. In 1971, Baxter built a major manufacturing plant in Ashdod, Israel and as a result, the company was placed on the Arab League boycott list in the early 1980s. Throughout the 1980s and 1990s the company expanded to deliver a wider variety of products and services (including vaccines, a greater variety of blood products) through acquisitions of various companies. Sales and production facilities also expanded throughout the world.
In March 2014, Baxter announced plans to create two separate, independent global healthcare companies-one focused on developing and marketing bio-pharmaceuticals and the other on medical products. The medical products company retained the name Baxter International Inc. and the bio-pharmaceuticals company is named Baxalta and spun off as a new public company that showed on trading boards as of July 1, 2015 .
About SANOFI-AVENTIS.
The company was incorporated in 1967 as Hoechst Pakistan Limited. Manufacture of pharmaceuticals and specialty chemicals began in 1973. In 1977 the company went public and was listed on the Karachi Stock Exchange. By virtue of several mergers, acquisitions and divestitures the company underwent several reincarnations over the years. Today, the company is Sanofi-Aventis Pakistan limited while the corporate identity is simply Sanofi. The extensive site in Karachi was founded in 1972, with an objective to develop, produce, package and distribute high-quality medicines under optimal safety conditions and at competitive costs to the market. Sanofi-Aventis Pakistan limited boasts a diversified pharmaceutical manufacturing facility, manufacturing products ranging from oral solids and liquid dosage forms to highly technical and sophisticated sterile products.